Céline Sabatel

Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China.

Sprouty2 Protein Regulates Hypoxia-inducible Factor-α (HIFα) Protein Levels and Transcription of HIFα-responsive Genes

Long-term outcome of Peripartum cardiomyopathy in a population with high seropositivity for Human Immunodeficiency Virus

NF-κB: a new player in angiostatic therapy

Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA)

A compendium of proteins that interact with HIF-1α

Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy

NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy

Age Sensitivity of NFκB Abundance and Programmed Cell Death in Erythrocytes Induced by NFκB Inhibitors

NF-κB, inflammation, immunity and cancer: coming of age

Lipid-mediated gene delivery to the skin

Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy

Reversal of IFN‐γ, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy

MicroRNAs and Cardiovascular Diseases

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems

Reviewing Peripartum Cardiomyopathy: Current State of Knowledge

MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer

MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells

Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth

Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis

The Angiostatic 16K Human Prolactin Overcomes Endothelial Cell Anergy and Promotes Leukocyte Infiltration via Nuclear Factor-κB Activation